Abstract
Antihyperlipidemic agents such as 3-hydroxymethyglutaryl-coenzyme A reductase inhibitors and cholesterol transporter inhibitors are used in coronary heart disease. However, controversy remains over the pharmacologic effects and safety of these drugs, especially when used in combination therapies. This retrospective study evaluated the therapeutic effect and safety of simvastatin 20 mg and ezetimibe 10 mg combination therapy compared to simvastatin 20 mg or ezetimibe 10 mg monotherapy in Korean patients according to gender, age, baseline low-density lipoprotein cholesterol, and cardiovascular risk factors. We observed significant differences among patient subgroups. Simvastatin and ezetimibe monotherapies and combination therapy reduced low-density lipoprotein cholesterol levels by 27.6%, 10.1%, and 36.8% (p < 0.001) and total cholesterol levels by 17.5%, 9.2%, and 25.3% (p < 0.001), respectively. Both monotherapy and combination therapy groups had similar incidences of all types of adverse events. However, one case of rhabdomyolysis was observed in the combination therapy group. These results suggest that, compared to monotherapy, combination therapy has an additive effect that is not influenced by risk factors. Despite the low incidence of adverse events, caution is required when using these drugs, especially in the context of musculoskeletal side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahn, S. C., Neuromuscular complications of statins. Phys. Med. Rehabil. Clin. N. Am., 19, 47–59 (2008).
Antons, K. A., Williams, C. D., Baker, S. K., and Phillips, P. S., Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med., 119, 400–409 (2006).
Bae, J. W., Kim, H. S., Lee, S. C., Han, K. H., and Jeon, E. S., The safety and efficacy of ezetimibe and simvastatin combination therapy in Korean patients with primary hypercholesterolemia. Kor. J. Int. Med., 68, 487–497 (2005).
Bays, H. E., Moore, P. B., Drehobl, M. A., Rosenblatt, S., Toth, P. D., Dujovne, C. A., Knopp, R. H., Lipka, L. J., Lebeaut, A. P., Yang, B., Mellars, L. E., Cuffie-Jackson, C., and Veltri, E. P., Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther., 23, 1209–1230 (2001).
Bhardwaj, S. S. and Chalasani, N., Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis., 11, 597–613 (2007).
Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., and Braunwald, E., Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J. Am. Coll. Cardiol., 52, 914–920 (2008).
Graham, D. J., Staffa, J. A., Shatin, D., Andrade, S. E., Schech, S. D., La Grenade, L., Gurwitz, J. H., Chan, K. A., Goodman, M. J., and Platt, R., Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 292, 2585–2590 (2004).
Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B. Jr., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C. Jr., and Stone, N. J., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227–239 (2004).
Nevzorov, R., Novack, V., Henkin, Y., Kobal, S. L., Jotkowitz, A., and Porath, A., Discrepancy between results of randomized control studies and retrospective analysis: the case of statin therapy effect on one-year mortality in patients with decompensated heart failure. Eur. J. Intern. Med., 20, 494–498 (2009).
O’Keefe, J. H. Jr., Cordain, L., Jones, P. G., and Abuissa, H., Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering of lowdensity lipoprotein. Am. J. Cardiol., 98, 135–139 (2006).
Pasternak, R. C., Smith, S. C. Jr., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., and Lenfant, C., ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke, 33, 2337–2341 (2002).
Pedersen, T. R., Intensive lipid-lowering therapy for patients with aortic stenosis. Am. J. Cardiol., 102, 1571–1576 (2008).
Pfefferkorn, J. A., ’Muscle-sparing’ statins: preclinical profiles and future clinical use. Curr. Opin. Investig. Drugs, 10, 245–252 (2009).
Qari, F. A., Severe rhabdomyolysis and acute renal failure secondary to use of simvastatin in undiagnosed hypothyroidism. Saudi J. Kidney Dis. Transpl., 20, 127–129 (2009).
Stamler, J., Wentworth, D., and Neaton, J. D., Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256, 2823–2828 (1986).
Stein, E. A., Lane, M., and Laskarzewski, P., Comparison of statins in hypertriglyceridemia. Am. J. Cardiol., 81, 66B–69B (1998).
Strandberg, T. E., Holme, I., Faergeman, O., Kastelein, J. J., Lindahl, C., Larsen, M. L., Olsson, A. G., Pedersen, T. R., and Tikkanen, M. J., Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am. J. Cardiol., 103, 1381–1385 (2009).
Wierzbicki, A. S., Newer, lower, better? Lipid drugs and cardiovascular disease — the continuing story. Int. J. Clin. Pract., 61, 1064–1067 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, YH., Kim, MJ., Choi, CI. et al. Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. Arch. Pharm. Res. 34, 1331–1337 (2011). https://doi.org/10.1007/s12272-011-0813-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0813-9